The findings of this large network meta-analysis are the first to provide information on the specific risk for DM
associated with different types and doses of statins. Because of the limited available direct evidence, large 95% CIs were
found around the overall estimates; in contrast, the stability of the results in several probability and ranking analyses make
the overall conclusions justified. If the findings of this network meta-analysis were confirmed in powered head-tohead
comparisons, they would have important implications for the future management of millions of individuals receiving
statins worldwide; indeed, a new scenario of statin therapy could be envisaged in which personalized statin therapy might
emerge as the most effective and safest strategy